Table 1

Baseline characteristics for all cohorts

Non-specific back painSpecific back painOsteoarthritis
Control
N=3.051
Intervention
N=21.247
Control
N=4.739
Intervention
N=31.269
Control
N=1.128
Intervention
N=23.042
Age (mean (SD))60.5 (15.8)60.5 (14.8)62.9 (15.0)63.3 (13.8)71.7 (11.4)68.9 (11.2)
Sex (female)59.2%65.5%62.7%64.7%66.0%66.3%
Level of care >0 (%)2.72.24.02.76.93.6
CCI (mean (SD))1.1 (1.6)1.6 (1.9)1.3 (1.8)1.8 (2.1)1.6 (1.9)2.2 (2.2)
Participation in disease management programme for type 2 diabetes12.0%17.2%12.5%19.7%16.0%24.4%
Cardiovascular comorbidities53.4%58.4%59.1%65.1%77.2%76.7%
Type 2 diabetes18.7%21.1%20.6%24.1%27.2%29.5%
Stroke and other cerebrovascular diseases1.3%1.9%1.8%2.2%2.2%2.8%
Malignancy8.1%11.6%10.6%13.0%14.6%16.0%
Obesity20.2%21.6%20.5%24.1%27.9%28.9%
Depression21.9%32.1%24.7%35.1%21.9%34.3%
Smoking6.0%6.7%6.3%6.6%3.9%4.8%
Psychosocial risk factors1.6%1.4%2.1%1.3%2.0%1.4%
Burnout8.1%6.4%8.7%6.9%5.7%5.5%
Somatoform disorders15.6%20.0%17.2%22.2%14.3%21.3%
MDPTO score (mean (SD))3.4 (1.7)3.7 (1.7)3.6 (1.6)4.0 (1.7)3.7 (1.8)4.1 (1.8)
  • T-test for count and continuous variables, Χ2 test for binary variables.

  • MDPTO score: a non-standardised score we developed and used in the model to approximate the level of musculoskeletal disease prior to the observation period. The score takes into account the following factors during the pre-observation period: hospitalisation related to musculoskeletal disorders, diagnosis of musculoskeletal disease, sickness certificate for musculoskeletal disorders, prescription of physical therapy or aids and appliances and prescription of opioids.

  • CCI, Charlson Comorbidity Index; MDPTO, musculoskeletal-disorder-prior-to-observation.